Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

WGRX vs DBVT vs HSIC vs ALKS vs MCK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
WGRX
Wellgistics Health, Inc.

Medical - Distribution

HealthcareNASDAQ • US
Market Cap$8M
5Y Perf.-96.9%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.+343.4%
HSIC
Henry Schein, Inc.

Medical - Distribution

HealthcareNASDAQ • US
Market Cap$8.09B
5Y Perf.-1.9%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+1.9%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$92.15B
5Y Perf.+15.0%

WGRX vs DBVT vs HSIC vs ALKS vs MCK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
WGRX logoWGRX
DBVT logoDBVT
HSIC logoHSIC
ALKS logoALKS
MCK logoMCK
IndustryMedical - DistributionBiotechnologyMedical - DistributionBiotechnologyMedical - Distribution
Market Cap$8M$1712.35T$8.09B$5.90B$92.15B
Revenue (TTM)$6M$0.00$13.18B$1.56B$403.43B
Net Income (TTM)$-73M$-168M$398M$153M$4.76B
Gross Margin4.1%29.1%65.4%3.6%
Operating Margin-12.1%5.8%12.3%1.5%
Forward P/E13.2x24.8x16.7x
Total Debt$25M$22M$3.69B$70M$7.39B
Cash & Equiv.$1M$194M$156M$1.12B$5.69B

WGRX vs DBVT vs HSIC vs ALKS vs MCKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

WGRX
DBVT
HSIC
ALKS
MCK
StockFeb 25May 26Return
Wellgistics Health,… (WGRX)1003.1-96.9%
DBV Technologies S.… (DBVT)100443.4+343.4%
Henry Schein, Inc. (HSIC)10098.1-1.9%
Alkermes plc (ALKS)100101.9+1.9%
McKesson Corporation (MCK)100115.0+15.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: WGRX vs DBVT vs HSIC vs ALKS vs MCK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MCK leads in 4 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. DBV Technologies S.A. is the stronger pick specifically for recent price momentum and sentiment. HSIC and ALKS also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
WGRX
Wellgistics Health, Inc.
The Healthcare Pick

Among these 5 stocks, WGRX doesn't own a clear edge in any measured category.

Best for: healthcare exposure
DBVT
DBV Technologies S.A.
The Momentum Pick

DBVT is the #2 pick in this set and the best alternative if momentum is your priority.

  • +110.4% vs WGRX's -98.0%
Best for: momentum
HSIC
Henry Schein, Inc.
The Defensive Pick

HSIC ranks third and is worth considering specifically for sleep-well-at-night.

  • Lower volatility, beta 0.73, Low D/E 76.9%, current ratio 1.38x
  • Better valuation composite
Best for: sleep-well-at-night
ALKS
Alkermes plc
The Quality Compounder

ALKS is the clearest fit if your priority is quality.

  • 9.8% margin vs WGRX's -13.0%
Best for: quality
MCK
McKesson Corporation
The Income Pick

MCK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 17 yrs, beta 0.04, yield 0.4%
  • Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
  • 348.1% 10Y total return vs HSIC's 5.3%
  • PEG 0.43 vs HSIC's 4.20
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthMCK logoMCK16.2% revenue growth vs DBVT's -100.0%
ValueHSIC logoHSICBetter valuation composite
Quality / MarginsALKS logoALKS9.8% margin vs WGRX's -13.0%
Stability / SafetyMCK logoMCKBeta 0.04 vs DBVT's 1.26
DividendsMCK logoMCK0.4% yield; 17-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)DBVT logoDBVT+110.4% vs WGRX's -98.0%
Efficiency (ROA)MCK logoMCK5.7% ROA vs WGRX's -138.4%, ROIC 5.4% vs -32.2%

WGRX vs DBVT vs HSIC vs ALKS vs MCK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

WGRXWellgistics Health, Inc.
FY 2024
Product
100.0%$18M
DBVTDBV Technologies S.A.

Segment breakdown not available.

HSICHenry Schein, Inc.
FY 2018
Healthcare Distribution
96.1%$12.7B
Technology
3.9%$509M
ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B

WGRX vs DBVT vs HSIC vs ALKS vs MCK — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMCKLAGGINGHSIC

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 5 of 6 comparable metrics.

MCK and DBVT operate at a comparable scale, with $403.4B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to WGRX's -13.0%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricWGRX logoWGRXWellgistics Healt…DBVT logoDBVTDBV Technologies …HSIC logoHSICHenry Schein, Inc.ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
RevenueTrailing 12 months$6M$0$13.2B$1.6B$403.4B
EBITDAEarnings before interest/tax-$65M-$112M$1.1B$212M$6.8B
Net IncomeAfter-tax profit-$73M-$168M$398M$153M$4.8B
Free Cash FlowCash after capex-$7M-$151M$561M$392M$6.0B
Gross MarginGross profit ÷ Revenue+4.1%+29.1%+65.4%+3.6%
Operating MarginEBIT ÷ Revenue-12.1%+5.8%+12.3%+1.5%
Net MarginNet income ÷ Revenue-13.0%+3.0%+9.8%+1.2%
FCF MarginFCF ÷ Revenue-130.5%+4.3%+25.1%+1.5%
Rev. Growth (YoY)Latest quarter vs prior year-80.9%+7.7%+28.2%+6.0%
EPS Growth (YoY)Latest quarter vs prior year-11.8%+91.5%+14.9%-4.1%+37.0%
ALKS leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

Evenly matched — DBVT and HSIC and MCK each lead in 2 of 7 comparable metrics.

At 21.6x trailing earnings, HSIC trades at a 26% valuation discount to MCK's 29.2x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.75x vs HSIC's 6.84x — a lower PEG means you pay less per unit of expected earnings growth.

MetricWGRX logoWGRXWellgistics Healt…DBVT logoDBVTDBV Technologies …HSIC logoHSICHenry Schein, Inc.ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
Market CapShares × price$8M$1712.35T$8.1B$5.9B$92.1B
Enterprise ValueMkt cap + debt − cash$32M$1712.35T$11.6B$4.9B$93.8B
Trailing P/EPrice ÷ TTM EPS-0.68x-0.76x21.56x24.76x29.25x
Forward P/EPrice ÷ next-FY EPS est.13.25x16.66x
PEG RatioP/E ÷ EPS growth rate6.84x0.75x
EV / EBITDAEnterprise value multiple10.87x17.25x18.74x
Price / SalesMarket cap ÷ Revenue0.44x0.61x4.00x0.26x
Price / BookPrice ÷ Book value/share0.68x0.66x1.79x3.28x
Price / FCFMarket cap ÷ FCF14.12x12.28x17.63x
Evenly matched — DBVT and HSIC and MCK each lead in 2 of 7 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 5 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-11 for WGRX. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to WGRX's 3.73x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs HSIC's 4/9, reflecting strong financial health.

MetricWGRX logoWGRXWellgistics Healt…DBVT logoDBVTDBV Technologies …HSIC logoHSICHenry Schein, Inc.ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
ROE (TTM)Return on equity-10.8%-130.2%+8.2%+8.8%+3.0%
ROA (TTM)Return on assets-138.4%-89.0%+3.6%+5.4%+5.7%
ROICReturn on invested capital-32.2%+7.1%+18.9%+5.4%
ROCEReturn on capital employed-73.4%-145.7%+9.8%+14.2%+30.5%
Piotroski ScoreFundamental quality 0–964476
Debt / EquityFinancial leverage3.73x0.13x0.77x0.04x
Net DebtTotal debt minus cash$24M-$172M$3.5B-$1.0B$1.7B
Cash & Equiv.Liquid assets$1M$194M$156M$1.1B$5.7B
Total DebtShort + long-term debt$25M$22M$3.7B$70M$7.4B
Interest CoverageEBIT ÷ Interest expense-10.95x-189.82x4.59x32.30x33.79x
MCK leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

MCK leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $232 for WGRX. Over the past 12 months, DBVT leads with a +110.4% total return vs WGRX's -98.0%. The 3-year compound annual growth rate (CAGR) favors MCK at 27.3% vs WGRX's -71.5% — a key indicator of consistent wealth creation.

MetricWGRX logoWGRXWellgistics Healt…DBVT logoDBVTDBV Technologies …HSIC logoHSICHenry Schein, Inc.ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
YTD ReturnYear-to-date-79.7%+4.9%-8.2%+25.3%-8.5%
1-Year ReturnPast 12 months-98.0%+110.4%+5.9%+16.5%+4.6%
3-Year ReturnCumulative with dividends-97.7%+19.7%-11.7%+14.5%+106.4%
5-Year ReturnCumulative with dividends-97.7%-69.1%-12.5%+60.9%+286.9%
10-Year ReturnCumulative with dividends-97.7%-87.0%+5.3%-11.0%+348.1%
CAGR (3Y)Annualised 3-year return-71.5%+6.2%-4.0%+4.6%+27.3%
MCK leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ALKS and MCK each lead in 1 of 2 comparable metrics.

MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs WGRX's 1.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricWGRX logoWGRXWellgistics Healt…DBVT logoDBVTDBV Technologies …HSIC logoHSICHenry Schein, Inc.ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
Beta (5Y)Sensitivity to S&P 5000.99x1.26x0.72x1.00x-0.02x
52-Week HighHighest price in past year$7.04$26.18$89.29$36.60$999.00
52-Week LowLowest price in past year$0.08$7.53$61.95$25.17$637.00
% of 52W HighCurrent price vs 52-week peak+1.3%+76.3%+79.0%+96.7%+75.3%
RSI (14)Momentum oscillator 0–10031.248.139.160.216.2
Avg Volume (50D)Average daily shares traded13.8M252K1.2M2.3M757K
Evenly matched — ALKS and MCK each lead in 1 of 2 comparable metrics.

Analyst Outlook

MCK leads this category, winning 1 of 1 comparable metric.

Analyst consensus: DBVT as "Buy", HSIC as "Hold", ALKS as "Buy", MCK as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 21.2% for HSIC (target: $85). MCK is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.

MetricWGRX logoWGRXWellgistics Healt…DBVT logoDBVTDBV Technologies …HSIC logoHSICHenry Schein, Inc.ALKS logoALKSAlkermes plcMCK logoMCKMcKesson Corporat…
Analyst RatingConsensus buy/hold/sellBuyHoldBuyBuy
Price TargetConsensus 12-month target$46.33$85.43$46.00$994.86
# AnalystsCovering analysts15322831
Dividend YieldAnnual dividend ÷ price+0.4%
Dividend StreakConsecutive years of raises01017
Dividend / ShareAnnual DPS$2.69
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+10.5%+0.5%+3.4%
MCK leads this category, winning 1 of 1 comparable metric.
Key Takeaway

MCK leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). ALKS leads in 1 (Income & Cash Flow). 2 tied.

Best OverallMcKesson Corporation (MCK)Leads 3 of 6 categories
Loading custom metrics...

WGRX vs DBVT vs HSIC vs ALKS vs MCK: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is WGRX or DBVT or HSIC or ALKS or MCK a better buy right now?

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — WGRX or DBVT or HSIC or ALKS or MCK?

On trailing P/E, Henry Schein, Inc.

(HSIC) is the cheapest at 21. 6x versus McKesson Corporation at 29. 2x. On forward P/E, Henry Schein, Inc. is actually cheaper at 13. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 43x versus Henry Schein, Inc. 's 4. 20x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — WGRX or DBVT or HSIC or ALKS or MCK?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -97. 7% for Wellgistics Health, Inc. (WGRX). Over 10 years, the gap is even starker: MCK returned +339. 0% versus WGRX's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — WGRX or DBVT or HSIC or ALKS or MCK?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.

02β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately -7786% more volatile than MCK relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 4% for Wellgistics Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — WGRX or DBVT or HSIC or ALKS or MCK?

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 14. 9% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — WGRX or DBVT or HSIC or ALKS or MCK?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -37. 8% for Wellgistics Health, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -33. 9% for WGRX. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is WGRX or DBVT or HSIC or ALKS or MCK more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 43x versus Henry Schein, Inc. 's 4. 20x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Henry Schein, Inc. (HSIC) trades at 13. 2x forward P/E versus 16. 7x for McKesson Corporation — 3. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

08

Which pays a better dividend — WGRX or DBVT or HSIC or ALKS or MCK?

In this comparison, MCK (0.

4% yield) pays a dividend. WGRX, DBVT, HSIC, ALKS do not pay a meaningful dividend and should not be held primarily for income.

09

Is WGRX or DBVT or HSIC or ALKS or MCK better for a retirement portfolio?

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

02), +339. 0% 10Y return). Both have compounded well over 10 years (MCK: +339. 0%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between WGRX and DBVT and HSIC and ALKS and MCK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: WGRX is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; HSIC is a small-cap quality compounder stock; ALKS is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

WGRX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

HSIC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 17%
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.